Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMETA Protocol for Neurocognitive Function in Alcohol Dependence
NCT00570388Phase 2Unknown
- Sponsor
- Institute of Addiction Medicine
- Start
- Mar 2007
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of flumazenil and gabapentin in alcohol dependence (2 arms), sponsored by Institute of Addiction Medicine. Primary endpoint: Neurocognitive Functioning at 8 weeks. Status: unknown.
02
Drugs
flumazenilgabapentin
03
Conditions
alcohol dependence
Beyond the preview
Go deeper on NCT00570388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570388.